| Jarrett Keller Sell, MD | |
|
2626 N 3rd St, Harrisburg, PA 17110-2044 | |
| (717) 232-5443 | |
| (717) 232-4553 |
| Full Name | Jarrett Keller Sell |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 24 Years |
| Location | 2626 N 3rd St, Harrisburg, Pennsylvania |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003888355 | NPI | - | NPPES |
| 102630256 | Medicaid | PA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | MD443689 (Pennsylvania) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Milton S Hershey Medical Center | Hershey, PA | Hospital |
| Pinnacle Health Hospitals | Harrisburg, PA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Alder Health Services, Inc. | 2163692641 | 5 |
| The Milton S Hershey Medical Center Physicians Group | 3870405483 | 1400 |
News Archive
Tranzyme Pharma today announced that it has entered into a strategic collaboration agreement with Bristol-Myers Squibb Company to discover, develop and commercialize novel macrocyclic compounds directed against targets of interest to Bristol-Myers Squibb.
Patients with hypertension whose blood pressure cannot be brought down to safe levels despite taking three or more medications may have some relief coming their way. An innovative, first-of-its-kind clinical trial for a device representing a dramatic shift in treatment approaches for the toughest-to-treat patients is currently being conducted at NewYork-Presbyterian Hospital.
The Gruenenthal Group and Forest Laboratories, Inc., today announced that Forest Healthcare B.V., a wholly owned subsidiary of Forest Laboratories, Inc. and Gruenenthal GmbH, have entered into an agreement whereby Forest has acquired all rights currently held by Gruenenthal for colistin and all rights previously licensed by Forest to Gruenenthal for Colobreathe.
Forty years ago, the first cases of HIV/AIDS in the U.S began to raise public awareness- but new research highlights the struggle people living with the disease still face against stigma, discrimination and negative labeling in their own families, communities and even amongst healthcare professionals.
The disturbed thinking, impaired judgment, impulsivity, and distractibility seen in mania, a destructive phase of bipolar disorder, may be traceable to overactivity of protein kinase C (PKC), suggests the study, funded by the National Institute of Mental Health (NIMH) and National Institute on Aging (NIA), and the Stanley Foundation.
› Verified 5 days ago
| Entity Name | The Milton S Hershey Medical Center Physicians Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1710951744 PECOS PAC ID: 3870405483 Enrollment ID: O20040225000741 |
News Archive
Tranzyme Pharma today announced that it has entered into a strategic collaboration agreement with Bristol-Myers Squibb Company to discover, develop and commercialize novel macrocyclic compounds directed against targets of interest to Bristol-Myers Squibb.
Patients with hypertension whose blood pressure cannot be brought down to safe levels despite taking three or more medications may have some relief coming their way. An innovative, first-of-its-kind clinical trial for a device representing a dramatic shift in treatment approaches for the toughest-to-treat patients is currently being conducted at NewYork-Presbyterian Hospital.
The Gruenenthal Group and Forest Laboratories, Inc., today announced that Forest Healthcare B.V., a wholly owned subsidiary of Forest Laboratories, Inc. and Gruenenthal GmbH, have entered into an agreement whereby Forest has acquired all rights currently held by Gruenenthal for colistin and all rights previously licensed by Forest to Gruenenthal for Colobreathe.
Forty years ago, the first cases of HIV/AIDS in the U.S began to raise public awareness- but new research highlights the struggle people living with the disease still face against stigma, discrimination and negative labeling in their own families, communities and even amongst healthcare professionals.
The disturbed thinking, impaired judgment, impulsivity, and distractibility seen in mania, a destructive phase of bipolar disorder, may be traceable to overactivity of protein kinase C (PKC), suggests the study, funded by the National Institute of Mental Health (NIMH) and National Institute on Aging (NIA), and the Stanley Foundation.
› Verified 5 days ago
| Entity Name | Alder Health Services, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1083911218 PECOS PAC ID: 2163692641 Enrollment ID: O20110822000015 |
News Archive
Tranzyme Pharma today announced that it has entered into a strategic collaboration agreement with Bristol-Myers Squibb Company to discover, develop and commercialize novel macrocyclic compounds directed against targets of interest to Bristol-Myers Squibb.
Patients with hypertension whose blood pressure cannot be brought down to safe levels despite taking three or more medications may have some relief coming their way. An innovative, first-of-its-kind clinical trial for a device representing a dramatic shift in treatment approaches for the toughest-to-treat patients is currently being conducted at NewYork-Presbyterian Hospital.
The Gruenenthal Group and Forest Laboratories, Inc., today announced that Forest Healthcare B.V., a wholly owned subsidiary of Forest Laboratories, Inc. and Gruenenthal GmbH, have entered into an agreement whereby Forest has acquired all rights currently held by Gruenenthal for colistin and all rights previously licensed by Forest to Gruenenthal for Colobreathe.
Forty years ago, the first cases of HIV/AIDS in the U.S began to raise public awareness- but new research highlights the struggle people living with the disease still face against stigma, discrimination and negative labeling in their own families, communities and even amongst healthcare professionals.
The disturbed thinking, impaired judgment, impulsivity, and distractibility seen in mania, a destructive phase of bipolar disorder, may be traceable to overactivity of protein kinase C (PKC), suggests the study, funded by the National Institute of Mental Health (NIMH) and National Institute on Aging (NIA), and the Stanley Foundation.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jarrett Keller Sell, MD Po Box 858, Mc A410, Hershey, PA 17033-0858 Ph: (800) 243-1455 | Jarrett Keller Sell, MD 2626 N 3rd St, Harrisburg, PA 17110-2044 Ph: (717) 232-5443 |
News Archive
Tranzyme Pharma today announced that it has entered into a strategic collaboration agreement with Bristol-Myers Squibb Company to discover, develop and commercialize novel macrocyclic compounds directed against targets of interest to Bristol-Myers Squibb.
Patients with hypertension whose blood pressure cannot be brought down to safe levels despite taking three or more medications may have some relief coming their way. An innovative, first-of-its-kind clinical trial for a device representing a dramatic shift in treatment approaches for the toughest-to-treat patients is currently being conducted at NewYork-Presbyterian Hospital.
The Gruenenthal Group and Forest Laboratories, Inc., today announced that Forest Healthcare B.V., a wholly owned subsidiary of Forest Laboratories, Inc. and Gruenenthal GmbH, have entered into an agreement whereby Forest has acquired all rights currently held by Gruenenthal for colistin and all rights previously licensed by Forest to Gruenenthal for Colobreathe.
Forty years ago, the first cases of HIV/AIDS in the U.S began to raise public awareness- but new research highlights the struggle people living with the disease still face against stigma, discrimination and negative labeling in their own families, communities and even amongst healthcare professionals.
The disturbed thinking, impaired judgment, impulsivity, and distractibility seen in mania, a destructive phase of bipolar disorder, may be traceable to overactivity of protein kinase C (PKC), suggests the study, funded by the National Institute of Mental Health (NIMH) and National Institute on Aging (NIA), and the Stanley Foundation.
› Verified 5 days ago
David Metzger, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 111 S Front St, Harrisburg, PA 17101 Phone: 717-231-8772 Fax: 717-231-8435 | |
Dr. Michael Timothy Partin, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 121 Nyes Road, Suite A, Hp09, Harrisburg, PA 17112 Phone: 717-657-4040 Fax: 717-671-9038 | |
Melissa Denham Gage, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 5125 Jonestown Rd Ste 105, Harrisburg, PA 17112 Phone: 717-943-1566 | |
Abraham Robert Taylor, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 121 N Nyes Rd Ste A, Harrisburg, PA 17112 Phone: 717-657-4040 Fax: 717-671-9038 | |
Dr. Denise F Montisano, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 805 Sir Thomas Ct, 2nd Floor, Harrisburg, PA 17109 Phone: 717-657-3030 Fax: 717-671-0991 | |
Dr. Bolanle Asuni Limann, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 110 S 17th St, Harrisburg, PA 17104 Phone: 717-232-9971 |